MedTrace Logo

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT06655246 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2026-02-05

No results posted yet for this study

Summary

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Conditions

  • Gastrointestinal Stromal Tumor (GIST)
  • Gastrointestinal Stromal Cancer
  • Gastrointestinal Stromal Neoplasm
  • Gastrointestinal Stromal Tumor, Malignant
  • Gastrointestinal Stromal Cell Tumors

Interventions

DRUG

ziftomenib

menin inhibitor

DRUG

imatinib mesylate

kinase inhibitor

Sponsors & Collaborators

  • Kura Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06655246 on ClinicalTrials.gov